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ABSTRACT
Infliximab is a commonly used antitumor necrosis factor alpha agent, especially in patients with inflammatory bowel disease. It has
been associated with drug-induced liver injury including immunologic reactions, with rare cases of acute liver failure. We describe
a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis
consistent with a diagnosis of vanishing bile duct syndrome. About 3 months after the initial infusion, the patient developed
subfulminant liver failure and required liver transplantation.
INTRODUCTION
Vanishing bile duct syndrome (VBDS) has been described as an immunologic drug-induced liver injury (DILI) with chronic
cholestasis and histopathological evidence of loss of intrahepatic bile ducts.1 The initial presentation is often severe cholestatic
hepatitis 1–6 months after exposure to previously reported medications including penicillins, fluoroquinolones, macrolides, anti-
convulsants, antipsychotics, antineoplastic agents, and nonsteroidal anti-inflammatory drugs.2 Workup often reveals persistently
elevated bilirubin and alkaline phosphatase despite improvement in liver inflammation. VBDS is a diagnosis of exclusion, with
alternate diagnoses including primary biliary cholangitis and primary sclerosing cholangitis. Liver histology is required for the
diagnosis of VBDS and typically shows a paucity of intralobular bile ducts in a sample taken at least 1month after the onset of injury.1
VBDS has been shown to be reversible but may progress to cirrhosis or liver failure.3 Tumor necrosis factor alpha (anti-TNF alpha)
inhibitors may slow progression; however, infliximab has been shown to cause DILI and induce autoimmune hepatitis possibly due
to its immunomodulatory properties.4–7 Anti-TNF alpha-induced liver failure has been reported but with different characteristics
when compared with anti-TNF alpha DILI.8 We describe a case of infliximab-induced VBDS leading to liver failure and an
orthotopic liver transplant.
CASE REPORT
A63-year-old African Americanmanwith ulcerative colitis presentedwith persistently elevated liver enzymes. The patient had been
on mercaptopurine and mesalamine for many years, but because of flare-ups and prednisone dependence, he was started on
infliximab 5mg/kg (470mg/dose).Hisfirst dosewas administered 3months before presentation, followed by a second and third dose
1 month apart, respectively. He had normal liver enzymes until 2 months before his first visit. His medications before elevation of
liver enzymes included infliximab, mercaptopurine, omeprazole, and prednisone. His examination was pertinent for scleral icterus,
a palpable liver edge at the costal margin, and jaundice. At that time, his bilirubin was 16 mg/dL, alkaline phosphatase 464 U/L,
alanine aminotransferase 1,164 U/L, and aspartate aminotransferase 896 U/L.
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At follow-up, his transaminases continued to increase until 2
months after the last infliximab dose at which point they im-
proved but remained above normal (Figure 1). His bilirubin, on
the other hand, continued to increase.Workup was negative for
viral hepatitis, smooth-muscle, anti-nuclear, andanti-mitochondrial
antibodies (immunoglobulin G [IgG] 989 mg/dL). Serum
ceruloplasmin and antitrypsin levels were also normal. An
abdominal ultrasound showed increased hepatic parenchymal
echogenicity and hepatomegaly. Bile ducts and spleen were
normal. A liver biopsy 3months after the initial infliximab dose
showed cholestatic hepatitis with patchy lobular necrosis,
ductopenia withmarked duct injury, andmild steatosis without
fibrosis (Figure 2). Hewas admitted to the hospital 2 weeks after
presentation because of clinical and biochemical features of
persistent cholestatic hepatitis with worsening bilirubin up to
55.3 mg/dL along with acute kidney injury, leukocytosis, and
hyponatremia.
Given aModel for End-Stage Liver Disease (MELD) score of 38
along with subfulminant hepatic failure, he underwent expe-
dited liver transplantation 3.5 months after his first dose of
infliximab. He was started on tacrolimus and methylprednis-
olone for both immunosuppression and to treat his ulcerative
colitis. The explanted liver pathology showed severe lobular
cholestasis with patchy hepatocyte necrosis with severe bile
duct injury and patchy bile duct loss (Figure 3). No fibrosis was
identified. The extrahepatic and large bile ducts were sampled
anddid not show evidence of primary sclerosing cholangitis. No
florid duct lesions or granulomas that would suggest primary
biliary cholangitis were identified on parenchymal sampling. A
diagnosis of autoimmune hepatitis was unlikely, given the lack
of prominence of plasma cells, interface activity, and fibrosis
along with the presence of marked cholestasis and duct injury/
loss withminimal inflammation on the explanted liver. Instead,
these findings are consistent with an infliximab-induced liver
injury with subsequent VBDS that required a liver transplant.
DISCUSSION
Although the diagnosis of VBDS is one of exclusion, many
features of this patient’s presentation and histopathology are
consistent with VBDS. Acute VBDS begins with persistent
cholestatic hepatitis, which was noted 3 months after the first
dose of infliximab and persisted until transplant. Although the
explanted liver was not ductopenic, there was patchy duct loss
with diffuse injury and degenerative changes of the remaining
Figure 1. Total bilirubin, alkaline phosphatase, and transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
before and after infliximab treatment. The laboratory values are represented as multiples of the normal upper limit.
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small ducts. Although VBDS is typically ductopenic, most
cases are diagnosed after years of progressive injury. This case
may have progressedmore rapidly, as may be the case in DILI-
associated cases of VBDS, with transplantation occurring
before the complete disappearance of the injured bile ducts.
Such patterns have been described with infliximab-induced liver
failure.8 A study of patients with drug-induced hepatitis that
included 11 cases of infliximab-induced liver injury showed that
45% of patients had an elevated IgG and 91% had an elevated
anti-nuclear antibody, but none had cholestatic liver damage.9 In
addition, infliximab has been reported to elicit transient serum
aminotransferase elevations and autoimmune features with
positive serum markers that respond to steroids.8 This pre-
sentation is different from the usual DILI related to anti-TNF
agents, given negative serologic and histological features of au-
toimmune hepatitis along with disease progression despite
treatment with prednisone and discontinuation of infliximab,
which suggests a different process. The timeframe of infliximab
administration with the subsequent cholestasis and bile duct
damage are consistent with VBDS, leading to liver failure. A
Roussel Uclaf Causality AssessmentMethod (RUCAM) score of 6
was calculated, which suggests a probable causal relationship be-
tween infliximab and the observed liver damage. In addition, this
patient developed liver injury after 3 infusions of infliximab over
12 weeks, which is consistent with previous reports of liver injury
induced by infliximab.6 Furthermore, the initial biopsy showed
portal and lobular inflammation, which was reduced on the
explanted liver despite persistentlyworseningbilirubin, suggesting
further loss of bile ducts despite improvement in inflammation,
a pattern seen in drug-induced VBDS. The mechanism is un-
known, but infliximab is the only chimeric mouse-human
monoclonal antibody of its class, which may explain the patho-
physiology.8 Although other medications have been implicated in
VBDS, this case is believed to represent the first case of infliximab-
inducedVBDSand liver failure that required liver transplantation.
Figure 3. (A) Hematoxylin and eosin stain of the explanted liver showing extensive hepatocyte dropout and marked cholestasis with minimal
lobular lymphocytic inflammation and no fibrosis (2003). (B) Cytokeratin 7 immunostain of the explanted liver showing the ductal epithelium
of a severely degenerative interlobular bile duct in a portal area (4003). There is minimal staining of periportal immature hepatocytes. No
significant ductular reaction is present, which would also stain with the immunostain, indicating minimal reconstitution of the ducts.
Figure 2. (A) Hematoxylin and eosin (H&E) stain of the pretransplant liver biopsy showingmixed portal inflammation, including lymphocytes,
plasma cells, and eosinophils (4003). Although present, plasma cells are not predominant. The portal vein and artery are readily identifiable,
but the duct is heavily infiltrated by inflammatory cells. No significant interface activity. (B) H&E stain of the pretransplant liver biopsy showing
marked lobular cholestasis with associated hepatocyte dropout and mild lobular lymphocytic inflammation (4003).
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